Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ADMA Biologics Inc (ADMA) vs GE Vernova Inc (GEV) Price & Performance

ADMA Biologics IncTrade
GE Vernova IncTrade

Price performance (Past 24H)

Key statistics

ADMA Biologics Inc vs GE Vernova Inc — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.22B), while GE Vernova Inc trades at $1,048 (market cap $269.50B). The key difference: GE Vernova Inc is far larger — about 121.4× ADMA Biologics Inc's market cap, and GE Vernova Inc pays a 0.2% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.

ADMAGEV
Market Cap
$2.22B$269.50B
Sector
HealthTechnology
52-Week High
$20.38$1.17K
52-Week Low
$7.60$547.96
Enterprise Value
$2.29B$259.17B
Dividend Yield
0.2%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ADMA Biologics Inc

ADMA trades at $9.78, up 0.31% today, with a bullish technical signal from moving averages and strong fundamentals including a 32.98% net income margin and 41.9% ROE. Recent earnings show a mix of beats and misses, with Q3 2026 EPS expected at $0.19. The stock faces headwinds from multiple class-action lawsuits alleging securities fraud, as reported by news outlets in August 2026.

Outlook is cautiously optimistic due to robust profitability and analyst support, but legal risks and recent earnings volatility pose challenges. Investment opportunity hinges on legal resolution and sustained earnings growth, with risks including litigation outcomes and competitive pressures in the biologics sector.

GE Vernova Inc

GE Vernova (GEV) trades at $1,039.90, up 4.95% in the last session, supported by strong technical momentum and bullish analyst sentiment. The company reported mixed Q2 2026 earnings with a miss on EPS expectations but maintains robust revenue growth and a massive $176 billion backlog. Valuation metrics remain elevated with a P/E of 29.01 and EV/EBITDA of 86.33, reflecting high growth expectations tied to AI-driven power demand.

Outlook remains positive given GEV's strategic positioning in AI infrastructure and energy transition, though premium valuation and execution risks on backlog conversion warrant caution. Strong institutional support with 76% buy ratings and consensus price target of $1,270 suggests upside potential, but investors should monitor quarterly execution against high expectations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ADMA Biologics Inc

ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.

Read more on ADMA

About GE Vernova Inc

GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.

Read more on GEV